Are the results of the SEAM-RA trial generalizable to other TNF inhibitors given the differences in immunogenicity?

This is a great question, and an important one because different TNF inhibitors have different immunogenicity and patients can make anti-drug antibodies that can effectively neutralize the drug and render it a less effective treatment option. This tends to happen more with some molecular constructs than others - for example, infliximab, which is a murine chimeric antibody, has more immunogenicity and a higher rate of anti-drug antibodies. Etanercept and certolizumab have lower immunogenicity and humanized monoclonal antibodies like adalimumab are probably somewhere in between.

The short answer is, we don’t know whether these results will be completely generalizable. Etanercept likely is a best case scenario in the sense that it has such low...